Generelt var emtricitabins farmakokinetik hos HBV- inficerede patienter den samme som hos raske forsøgspersoner og hos HIV- inficerede patienter.
In general, emtricitabine pharmacokinetics in HBV infected patients were similar to those in healthy subjects and in HIV infected patients.